2-acetilnafto<2,3-b>furano | 87004-83-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 萘并呋喃类
• 英文名称: 2-acetilnafto<2,3-b>furano
• 英文别名: Ethanone, 1-naphtho[2,3-b]furan-2-yl-；1-benzo[f][1]benzofuran-2-ylethanone
• CAS: 87004-83-9
• 化学式: C₁₄H₁₀O₂
• 分子量: 210.232
• InChiKey: HSJXTSHSSGRADD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Novel lapacho compounds and methods of use thereof
  申请人：Muller Klaus

  公开号：US20060142271A1

  公开（公告）日：2006-06-29

  The invention provides new synthetic lapacho derivatives as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders. These compounds can also be used in the treatment or prevention of psoriasis or cancer or precancerous conditions.

  本发明提供了新的合成拉帕昔衍生物及其使用方法。这些化合物可以用于制备药物组合物，用于治疗或预防细胞增殖障碍。这些化合物还可以用于治疗或预防牛皮癣、癌症或癌前病变。
• NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF
  申请人：ARQULE, INC.

  公开号：EP1551392A2

  公开（公告）日：2005-07-13
• METHODS FOR TREATING CANCER
  申请人：Boston Biomedical, Inc.

  公开号：EP3283070A1

  公开（公告）日：2018-02-21
• [EN] NOVEL LAPACHO COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] NOUVEAUX COMPOSES DE LAPACHO ET PROCEDES D'UTILISATION ASSOCIES
  申请人：MULLER KLAUS

  公开号：WO2004026253A2

  公开（公告）日：2004-04-01

  The invention provides new synthetic lapacho derivatives as well as methods of use thereof. These compounds can be used in pharmaceutical compositions for the treatment or prevention of cell proliferation disorders. These compounds can also be used in the treatment or prevention of psoriasis or cancer or precancerous conditions.
• [EN] METHODS FOR TREATING CANCER<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER
  申请人：BOSTON BIOMEDICAL INC

  公开号：WO2016168858A1

  公开（公告）日：2016-10-20

  Methods comprising administration of and kits comprising at least one compound of formula (I); and at least one additional anti-cancer therapy chosen from panitumumab, cetuximab, capecitabine, CAPOX, regorafenib, and FOLFOX.